Specialty Pharmacy Clinical Policy Bulletins Aetna Non-Medicare Prescription Drug Plan
Subject: Camzyos SGM 5268-A P2025
Drug
CAMZYOS(mavacamten)
Policy:
Indications
The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.
FDA-approved Indications1
Camzyos is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.
All other indications are considered experimental/investigational and not medically necessary.
Documentation
Submission of the following information is necessary to initiate the prior authorization review:
Initial requests
Imaging reports, chart notes, or medical record documentation supporting left ventricular wall thickness.
Laboratory results, chart notes, or medical record documentation of familial hypertrophic cardiomyopathy or a positive genetic test (e.g., MYH7, MYBPC3, TNNI3, TNNT2, TPM1, MYL2, MYL3, ACTC1 gene variants) (if applicable).
Chart notes or medical record documentation supporting baseline left ventricular ejection fraction (LVEF) ≥ 55% and baseline Valsalva left ventricular outflow tract (LVOT) peak gradient ≥ 50 mmHg.
Chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. If therapy is not advisable, documentation of clinical reason to avoid therapy.
Continuation requests
Chart notes or medical record documentation supporting a positive clinical response to therapy (e.g., increase in peak oxygen consumption [pVO2], NYHA class reduction).
Chart notes or medical record documentation supporting left ventricular ejection fraction (LVEF) ≥ 50%.
Coverage Criteria
Obstructive Hypertrophic Cardiomyopathy1,2,4-6
Authorization of 3 months may be granted for treatment of obstructive hypertrophic cardiomyopathy when all of the following criteria are met:
Member has one of the following:
Left ventricular wall thickness of greater than or equal to 15 mm anywhere in the left ventricle.
Left ventricular wall thickness of greater than or equal to 13 mm anywhere in the left ventricle in members with familial hypertrophic cardiomyopathy or a positive genetic test (e.g., MYH7, MYBPC3, TNNI3, TNNT2, TPM1, MYL2, MYL3, ACTC1 gene variants).
Member has NYHA functional class II to class III symptoms (see Appendix).
Member must have a baseline left ventricular ejection fraction (LVEF) ≥ 55% and baseline Valsalva left ventricular outflow tract (LVOT) peak gradient ≥ 50 mmHg.
Member has experienced an inadequate response to a beta-adrenergic antagonist (e.g., atenolol, metoprolol) or non-dihydropyridine calcium channel blocker (diltiazem, verapamil) at maximally tolerated dose, or has an intolerance or contraindication to both therapies.
Continuation of Therapy
Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for obstructive hypertrophic cardiomyopathy when both of the following criteria are met:
The member has achieved or maintained a positive clinical response to therapy (e.g., increase in pVO2, NYHA class reduction).
Member has a left ventricular ejection fraction (LVEF) ≥ 50%.
Appendix
New York Heart Association (NYHA) Functional Classification3
NYHA Grading
Class I
No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath.
Class II
Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain.
Class III
Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.
Class IV
Symptoms of heart failure at rest. Any physical activity causes further discomfort.
Place of Service:
Outpatient
The above policy is based on the following references:
Camzyos [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; April 2025.
Ommen SR, Ho CY, Balaji S, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the management of hypertrophic cardiomyopathy: A report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. Circulation. 2024;149(23):e1239-e1311.
Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomized, double-blind placebo-controlled, phase 3 trial. Lancet. 2021;397(10293):2467-2475.
Maron B, Desai M, Nishimura R, et al. Management of Hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022;79(4):390-414.
Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
